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Abstract
Background: Cancer remains one of the most complex diseases affecting humans and, despite the
impressive advances that have been made in molecular and cell biology, how cancer cells progress
through carcinogenesis and acquire their metastatic ability is still widely debated.
Conclusion: There is no doubt that human carcinogenesis is a dynamic process that depends on
a large number of variables and is regulated at multiple spatial and temporal scales. Viewing cancer
as a system that is dynamically complex in time and space will, however, probably reveal more
about its underlying behavioural characteristics. It is encouraging that mathematicians, biologists
and clinicians continue to contribute together towards a common quantitative understanding of
cancer complexity. This way of thinking may further help to clarify concepts, interpret new and old
experimental data, indicate alternative experiments and categorize the acquired knowledge on the
basis of the similarities and/or shared behaviours of very different tumours.
Background
There is no doubt that cancer operates at the different lev-
els of the hierarchical organization making up a human,
and evolves through an assortment of states (or possible
pattern configurations) and a number of transitions between
two successive states [1,2].
According to the reductionist view of cancer, expressed in
myriads of molecular biology-based investigations, all the
information necessary for a cell to transform itself into a
neoplastic cell can be attributed to changes at the genomic
level. This "certainty" is based on the fact that the genome
carries all of the information related to any cell process,
and that any cellular transformation is due to a specific
genomic change. Although this approach has offered and
remains a fundamental means of generating knowledge
[3-7], the accumulated information has also raised a
number of fascinating questions. How many distinct reg-
ulatory circuits within each type of target cell must be dis-
rupted in order to make it become cancerous? Is the same
set of cell regulatory circuits disrupted in the cells of the
disparate neoplasms arising in humans? And, if we had a
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complete explanation of all of the molecular reactions
occurring within a living normal cell and its tumoral
counterpart, would we understand that cell?
Reductionism seeks to interpret the wide variety of natural
phenomena on the basis of the behaviour of a restricted
number of basic constituents subject to simple but rigor-
ous laws [8-10]. It has been a powerful driving force in sci-
ence, as can be clearly seen from the impressive triumphs
of molecular and cell biology. However, the question
remains as to how to transform this molecular knowledge
into an understanding of the complex phenomena exist-
ing in genes, sub-cellular entities, cells, tissues, organs,
apparatuses and the body as a whole [8-18].
The need to tackle systemic complexity has become even
more apparent since the completion of the various
genome projects [19,20], which have stimulated a search
for new ways of understanding the complex processes
underlying cancer initiation, progression and metastasis [19-
23].
Initiation and progression of cancers
Cancer is today recognized as a highly heterogeneous dis-
ease: more than 100 distinct types of human cancer have
been described, and various tumour subtypes can be
found within specific organs [2,24]. In addition, tumours
have somatic mutations and epigenetic changes, many of
which are specific to the individual neoplasm [25]. It is
now recognized that this genetic and phenotypical varia-
bility primarily determines the self-progressive  growth,
invasiveness and metastatic potential of neoplastic dis-
ease and its response or resistance to therapy, and it seems
that the multi-level complexity of cancer explains the clin-
ical diversity of histologically similar neoplasia [2].
Analysis of the initiation and progression of cancer cells
from natural (normal) cells and the heterogeneity of a
cancer population raises two intriguing questions:
￿ what are the properties shared by cancer and natural
cells?
￿ to what extent are these properties shared?
Both natural and tumoral cells are networks of sub-cellu-
lar anatomical entities organized in such a way as to per-
form all of the complex functions necessary to guarantee
the cell's existence. The simplified set of real properties (i.e.
characteristics) defining a natural cell can be written as:
A = {a, b, c, d, e, f, g, h}   (1)
where A is the set and the letters a, b, c...h indicate its ele-
ments or members: i.e. the cell's properties. Similarly, the
simplified set of real properties defining a cancer cell can
be written as:
B = {f, g, h, i, l, m, n}   (2)
where B is the set and the letters f, g, h...n indicate its ele-
ments or members. Using the graphical form suggested by
Eulero-Venn [26], the two sets A and B can be drawn as in
Figure 1.
Some elements of sets A and B (f, g, h) are shared by nat-
ural and tumoral cells; this can be depicted graphically as
the area of intersection between A and B (Figure 2). An
important property relating the number of members of a
set to their unions and intersections is:
n(A) + n(B) - n(A∩B) = n(A∪B)   (3)
In simplified terms, it can be assumed that the area of
intersection is proportional to the number of properties
shared by the two sets A and B.
On the basis of the above, it is possible to build the
schema in Figure 3, which shows the hypothetical dichot-
omous initiation and progression of a cancer cell as: (a) a
distinct anatomical cell entity; or (b) an anatomical entity
that retains a number of the characteristics of a natural
cell.
Natural and cancer cells are two distinct entities, each with
its own pattern of properties determining its distinctive
functions and/or behaviours: in other words, the genera-
tion of a final anatomical entity characterized by its own
set of elements indicates that the starting set A and the
final set B are distinct (Figure 3a). If we consider the area
of intersection as proportional to the number of shared
Natural cells and their tumoural counterparts can be viewed  as sets of different entities and/or behaviours Figure 1
Natural cells and their tumoural counterparts can be viewed 
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characteristics, the complete loss of this area over time
generates a distinct entity (Figure 3a). In symbols,
A ∩ B = ∅   (4)
In contrast, progressive but limited reduction of the area
of intersection (Figure 3b) leads to a final cell that retains
some of the characteristics of a normal cell but has a
number of distinct properties that are responsible for its
tumoral nature i.e. tumour growth, invasiveness, metastatic
potential and responsiveness or resistance to therapy.
Consequently, the shared properties that are retained
between the two sets A and B may result in collateral
effects or toxicity during therapeutic regimens.
It is interesting to note that the asynchrony and self-progres-
sion of a cancer cell population suggest that the extent to
which each neoplastic cell shares the properties of a natu-
ral cell may differ in time and in space. It is also worth
pointing out that the differences or similarities between
natural and cancer cells may involve both qualitative and
quantitative aspects.
Recently, the development of recurrent cancers and sec-
ond primary tumours (SPTs) has been explained by the
concept of "field cancerization" [28]. In the original paper
by Slaughter et al., field cancerization was defined as fol-
lows: (a) oral cancer develops in multi-focal areas of pre-
cancerous change, (b) histologically abnormal tissue
surrounds the tumours, (c) oral cancer often consists of
multiple independent lesions that sometimes coalesce,
The progressive transformation of natural cells into cancer cells Figure 3
The progressive transformation of natural cells into cancer cells. This schema shows the dichotomous generation of a cancer 
cell as a distinct entity (a) or with a number of functions shared with a natural cell. The area of the intersection is proportional 
to the number of shared properties: a zero area indicates that the cancer cell is a wholly distinct entity, whereas its progressive 
but time-limited reduction leads to a cell that has a proportion of shared behaviours and a proportion of distinct properties 
that determine its tumoural nature i.e. tumour growth, invasiveness, metastatic potential and responsiveness or resistance to 
therapy (b).
Natural and tumoural cells share a number of properties  (green area), and this sharing can be schematized using set  theory Figure 2
Natural and tumoural cells share a number of properties 
(green area), and this sharing can be schematized using set 
theory.Theoretical Biology and Medical Modelling 2006, 3:37 http://www.tbiomed.com/content/3/1/37
Page 4 of 6
(page number not for citation purposes)
and (d) the persistence of abnormal tissue after surgery
may explain SPTs and local recurrences [29]. Genetic anal-
yses have been performed to substantiate the observation
of Slaughter et al. that tissue adjacent to a tumour can be
aberrant. Importantly, many investigators have found
cancer-associated genetic alterations in tumour-adjacent
"macroscopically normal" tissue and its margins [27,28].
Fields with genetically altered cells can be large (up to 7
cm in diameter). These lesions may not be apparent on
histopathological investigation but can be detected by
molecular analyses for phenotypic or genetic alterations
associated with carcinogenesis such as p53 gene muta-
tions, integrated viral DNA, loss of heterozygosity and
microsatellite instability. Field cancerization has been
described for lung, oesophagus, vulva, cervix, anus, colon,
breast, bladder and skin in addition to the oral cavity,
pharynx and larynx [27,28].
In the experimental sciences, observed patterns can often
be conceptualized as macro-scale manifestations of micro-
scale processes. However, in many cases, a more typical sit-
uation involves observed patterns or system states that are
created or influenced by multiple processes and controls [30].
Cancer is determined by a number of processes and con-
trols operating over much broader scales, and by factors
such as structural controls that may operate at scales rang-
ing from molecular to environmental [2]. This multiple
scale causality not only recognizes multiple processes and
controls acting at multiple scales but, in contrast to a
strictly reductionist approach, may also recognize that rel-
evant "first principles" may reside at scales other than the
smallest micro-scales. In other words, the observed phe-
nomenon at each scale has structural and behavioural
properties that do not exist at lower or higher organiza-
tional levels [2].
Furthermore, it is necessary to consider that the complex
environment in which a normal or cancer cell is embedded
determines a different cell-environment interchange of mat-
ter, energy and information, thus inducing continuous qual-
itative and/or quantitative changes in the shared
properties and/or behaviours. The milieu of environmen-
tal effects responsible for the genesis of neoplastic precur-
sor cells is often associated with autoimmune or chronic
inflammatory reactions induced by biological agents,
endogenous and exogenous chemicals, and physical
agents such as heat, radiation and foreign bodies [31].
Conclusive key-points
On the basis of the above, there is no doubt that human
carcinogenesis is a complex dynamic process that depends
on a large number of variables and is regulated at multiple
spatial and temporal scales, thus making it one of the most
intricate phenomena in biology [2].
In mathematical terms, carcinogenesis is a non-linear proc-
ess, the behaviour of which does not follow clearly pre-
dictable and repeatable pathways. In linear systems, the
behaviour of a system changes linearly in response to an
environmental factor that influences it. In contrast, the
behaviour of non-linear complex systems may be per-
ceived as surprising and unpredictable [32]. Periods of inac-
tivity may be punctuated by sudden change, apparent
patterns of behaviour may disappear and new patterns
may unexpectedly emerge [2]. Moreover, non-linear sys-
tems do not react proportionally to the magnitude of their
inputs, and depend on their initial conditions, i.e.  small
changes in the initial conditions may generate very differ-
ent end-points. These characteristics are frequently high-
lighted by the frequency with which differences in
progression or therapeutic response are seen in the same
tumour type, and by the fact that cancer morphology does
not always reveal a similar underlying biology. It is also
necessary to emphasize that cancer does not conform to
simple mathematical principles: the irregular mode of car-
cinogenesis, erratic tumour growth, variable response to
tumoricidal treatments, and poorly understood metastatic
patterns constitute highly variable clinical behaviours.
After the complete resection of a carcinoma preserving
part of the organ in which it developed, microscopically
normal but genetically altered epithelium may remain in
situ and acquire additional mutations or epigenetic alter-
ations that can initiate the development of a second
tumor of the same or a different histological type, repre-
senting an in situ recurrence. Local recurrences develop at
the site of the primary surgery/surgical scar (scar recur-
rences) or at some distance from this location in the resid-
ual organ that remained in situ after resection (in situ
recurrences). Discrimination between these two types of
local recurrence is important as their different prognoses
point to differences in their pathogenesis.
Recently, Tabor et al. [33] have shown that in a propor-
tion of patients with primary head and neck tumours, the
primary tumour and the SPT develop from a single contig-
uous genetically-altered field and thus have a common
clonal origin. In other patients, the first and second pri-
mary tumours develop independently from genetically
unrelated fields [33]. The picture that emerges is that in
the second primary tumor patients, large areas of the nor-
mal mucosa have been replaced by one or more mono-
clonal cell populations [33].
In conclusion, the above reflections have led us to think
that:
(1) Cancer is a highly complex disease in time and in
space [2,34-37].Theoretical Biology and Medical Modelling 2006, 3:37 http://www.tbiomed.com/content/3/1/37
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(2) Cancer is a hierarchical system. The decisive step in
carcinogenesis is the result of an irreversible qualitative
change in one or more of the genetic characteristics of can-
cer cells. Although this modification governs the transfor-
mation of normal human cells into malignant cancer
cells, it may or may not lead to visible changes in their
cytological or histological structures [2]. This can be
explained using the concept of emergence, which defines
humans as complex systems consisting of different ana-
tomical entities that are interconnected at many organiza-
tional levels (a hierarchical system), have various degrees
of complexity, and are governed by specific laws that only
operate at a particular level [2].
(3) First proposed for oral cancer by Slaughter et al. [29],
field cancerization describes clinically occult multifocal
precancerous lesions of the epithelium within an anatom-
ical region exposed to the same carcinogen(s) [e.g. ciga-
rette smoking, human papillomavirus (HPV) infection].
Current adjuvant treatment modalities are effective in
eradicating tumor cells, but these may not be the treat-
ment of choice for relatively large fields of precancerous
cells. Moreover, the shared properties retained between
the two sets A and B (Figure 3) may result in collateral
effects or toxicity during the therapeutic regimens.
(4) Although the alterations usually occur at a characteris-
tic stage of tumour advancement, experimental evidence
indicates that the ongoing accumulation of changes is
more important than their order of occurrence in the
course of cancer [2]. In physical terms, it is true that alter-
ations in one parameter (i.e. chromosomal changes, DNA
changes, specific gene changes or mitochondrial changes)
are not necessarily associated with the loss of stability of a
system, and it is also true that an unstable system is more
sensitive to small changes in parameters (i.e. its state is
more easily modifiable). In biological terms, a growing
network of cancer-susceptibility genes is formed as the
neoplasm advances [2]. The human genome is typically so
stable that the many genetic alterations required for can-
cer to develop cannot accumulate unless the rate of muta-
tion increases to the point of making it genetically
unstable [2,38].
(5) Considering cancer as a robust system [i.e. the ability of
a living system to maintain performance (phenotypic stabil-
ity) in the face of perturbations arising from environmen-
tal changes, stochastic events (or intracellular noise) and
genetic variations] would provide us with a framework for
future research strategies, and future cancer therapies may
be judged on their ability to help control the robustness of
tumours [2,39].
(6) Modelling the growth and development of human
tumours using mathematics and biological data is a bur-
geoning area of cancer research. Mathematical methods
and their derivatives have proved to be possible and prac-
tical in oncology [40], but the current models are often
simplifications that ignore vast amounts of knowledge:
for example, most metabolic models seem to regard a cell
as a bag of enzymes, neglecting its spatial heterogeneity
and compartmentalisation [2]. Furthermore, most mod-
els struggle to resolve the 10–12 order-of-magnitude span
of the timescales of systemic events, be they molecular
(ion channel gating: 10-6 s), cellular (mitosis: 102–103 s)
or physiological (cancer progression: 108 s) [2].
Viewing cancer as a system that is dynamically complex in
time and space will, however, probably reveal more about
its underlying behavioural characteristics. It is encourag-
ing that mathematicians, biologists and clinicians con-
tinue to contribute together towards a common
quantitative understanding of cancer complexity [1,2,40-
43]. This way of thinking may further help to clarify con-
cepts, interpret new and old experimental data, indicate
alternative experiments and categorize the acquired
knowledge on the basis of the similarities and/or shared
behaviours of very different tumours.
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